Is Controlling Inflammation Enough? Rethinking Fibrosis and the Role of TL1A-Targeted Therapies in IBD Care for Advanced Practice Providers

Supported by an educational grant from Genentech, a member of the Roche Group. This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.